Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,164,591

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $150.00 -3.49 (-2.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

    Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

    Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.

      Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife

      Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.

        Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

        Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

          PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

          PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

            OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2

            OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.

              Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View

              Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.

                Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

                Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.

                  Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2

                  Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.

                    CBM vs. ILMN: Which Stock Should Value Investors Buy Now?

                    CBM vs. ILMN: Which Stock Is the Better Value Option?

                      Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                      Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                        Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                        Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                          DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance

                          DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.

                            Luminex (LMNX) Misses on Earnings in Q2, Margins Contract

                            Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.

                              Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates

                              Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.

                                Cardinal Health (CAH) Surpasses Earnings Estimates in Q4

                                Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.

                                  Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates

                                  Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.

                                    Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y

                                    Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.

                                      Pacific Biosciences (PACB) Loss In Line With Estimates in Q2

                                      Strong performance in Product revenues boosts Pacific Biosciences (PACB) in Q2. Sequel order improves year over year.

                                        DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View

                                        Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.

                                          Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid

                                          Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.

                                            The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision

                                            The Zacks Analyst Blog Highlights: Microsoft, Micron, Amazon.com, Illumina and Activision

                                              CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance

                                              CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.

                                                Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance

                                                Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.

                                                  DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                                                  Year-over-year growth in net dialysis and related lab patient service revenues boost DaVita's (DVA) bottom line in Q2.